iRadimed (NASDAQ:IRMD) CEO Sells $261,144.06 in Stock

iRadimed Corporation (NASDAQ:IRMD) CEO Roger Susi sold 3,089 shares of the stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $84.54, for a total transaction of $261,144.06. Following the completion of the sale, the chief executive officer directly owned 2,184,411 shares in the company, valued at approximately $184,670,105.94. This trade represents a 0.14% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

iRadimed Stock Down 0.5%

IRMD stock opened at $86.44 on Friday. iRadimed Corporation has a fifty-two week low of $50.88 and a fifty-two week high of $107.90. The firm’s 50-day simple moving average is $93.68 and its 200 day simple moving average is $94.67. The stock has a market cap of $1.10 billion, a PE ratio of 47.24 and a beta of 0.90.

iRadimed (NASDAQ:IRMD) last released its earnings results on Friday, May 1st. The medical equipment provider reported $0.49 EPS for the quarter, beating the consensus estimate of $0.46 by $0.03. The firm had revenue of $21.98 million for the quarter, compared to analysts’ expectations of $21.32 million. iRadimed had a net margin of 27.36% and a return on equity of 24.48%. iRadimed has set its FY 2026 guidance at 2.060-2.210 EPS and its Q2 2026 guidance at 0.440-0.480 EPS. Equities analysts forecast that iRadimed Corporation will post 1.52 EPS for the current fiscal year.

iRadimed Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, May 29th. Shareholders of record on Friday, May 15th will be paid a dividend of $0.20 per share. The ex-dividend date of this dividend is Friday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed’s dividend payout ratio (DPR) is presently 43.72%.

Hedge Funds Weigh In On iRadimed

Large investors have recently made changes to their positions in the business. SG Americas Securities LLC boosted its position in shares of iRadimed by 88.6% during the 4th quarter. SG Americas Securities LLC now owns 70,391 shares of the medical equipment provider’s stock valued at $6,848,000 after purchasing an additional 33,072 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of iRadimed during the 3rd quarter valued at about $422,000. Tudor Investment Corp ET AL bought a new position in shares of iRadimed during the 3rd quarter valued at about $666,000. RFG Advisory LLC bought a new position in shares of iRadimed during the 4th quarter valued at about $1,594,000. Finally, Baader Bank Aktiengesellschaft bought a new position in shares of iRadimed during the 4th quarter valued at about $595,000. Institutional investors own 92.34% of the company’s stock.

Wall Street Analyst Weigh In

IRMD has been the topic of several research analyst reports. Lake Street Capital reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Wednesday, February 11th. Freedom Capital raised shares of iRadimed to a “strong-buy” rating in a research note on Thursday, April 2nd. Roth Mkm reissued a “buy” rating and set a $120.00 target price on shares of iRadimed in a research note on Tuesday, February 10th. Finally, Weiss Ratings raised shares of iRadimed from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, May 6th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the company’s stock. According to data from MarketBeat.com, iRadimed presently has a consensus rating of “Buy” and a consensus target price of $120.00.

iRadimed Company Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.